Terlipressin subcutaneous - NanoAntibiotics /PharmaIN

Drug Profile

Terlipressin subcutaneous - NanoAntibiotics /PharmaIN

Alternative Names: PGC-C12E-Terlipressin; PHT 101; SC terlipressin- NanoAntibiotics /PharmaIN

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LAT Pharma; PharmaIN
  • Developer BioVie
  • Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ascites
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ascites

Most Recent Events

  • 11 May 2017 BioVie plans a phase II trial for Ascites in USA (NCT03107091)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Ascites in USA (SC, Controlled release)
  • 15 Jul 2016 Chemical structure info added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top